FIXED ANTIHYPERTENSIVE DRUGS COMBINATION SELECTION WITH THE AIM OF ORGANS PROTECTION

The article focuses on the problems of choice among the antihypertension drugs combinations according to organs protection properties. It is underlined that target organs damage (microalbuminuria, pulse wave rate velocity increase, myocardial hypertrophy of the left ventricle, atherosclerotic plaques in carotid arteries) are independent predictors of cardiovascular mortality. Optimal combinations of antihypertension drugs are reviewed taking kidney damage, vessel wall damage, the heart and the brain. The data provided on organs protective properties of lercanidipine, enalapril and fixed combination of them

The use of short-acting bronchodilators in patients with chronic bronchoobstructive pathology at the present stage

Inhaled short-acting bronchodilators (beta-agonists and M-anticholinergics) have been used for a long time in patients with bronchoobstructive diseases, the main representatives of which are chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA). Given the fact that most patients with COPD and BA are treated with long-acting bronchodilators, the question arises about the place of short-acting drugs in modern treatment algorithms for bronchoobstructive pathology. The data on how many patients take short-acting beta-agonists and M- anticholinergics in real-life clinical practice, and how appropriate it is to use these drugs on top of prolonged drugs are provided. The Russian part of the international POPE-study analyzed the characteristics of outpatients with COPD. It was found that the vast majority of patients have short-acting bronchodilators as part of their therapy, and more than 50% of patients receive a combination of SABA and SAAC, and in most cases this is represented by a combination of fenoterol + ipratropium. Taking into account that the majority of patients with COPD and asthma receive prolonged bronchodilators, important from a practical point of view is the question of the effectiveness of short-acting drugs on the background of prolonged ones. The article discusses these aspects of therapy and provides evidence that the use of SABA and SAAC provides an opportunity to achieve additional bronchodilatation when used against the background of prolonged bronchodilators. Thus, symptomatic use of SABA and SAAC on demand in bronchoobstructive pathology have sufficient justification even in the presence of a combination of prolonged bronchodilators in patient therapy. At the same time, it is necessary to take into account the increased probability of side effects with such drug regimen. The article also discusses the issues of different types of inhalation devices for short-acting bronchodilators (nebulizers and metered-dose aerosol inhalers), provides data on their comparative effectiveness and safety

Flamelet Model Application for Non-Premixed Turbulent Combustion

The current Final Report contains results of the study which was performed in Scientific Research Center 'ECOLEN' (Moscow, Russia). The study concerns the development and verification of non-expensive approach for modeling of supersonic turbulent diffusion flames based on flamelet consideration of the chemistry/turbulence interaction (FL approach). Research work included: development of the approach and CFD tests of the flamelet model for supersonic jet flames; development of the simplified procedure for solution of the flamelet equations based on partial equilibrium chemistry assumption; study of the flame ignition/extinction predictions provided by flamelet model. The performed investigation demonstrated that FL approach allowed to describe satisfactory main features of supersonic H 2/air jet flames. Model demonstrated also high capabilities for reduction of the computational expenses in CFD modeling of the supersonic flames taking into account detailed oxidation chemistry. However, some disadvantages and restrictions of the existing version of approach were found in this study. They were: (1) inaccuracy in predictions of the passive scalar statistics by our turbulence model for one of the considered test cases; and (2) applicability of the available version of the flamelet model to flames without large ignition delay distance only. Based on the results of the performed investigation, we formulated and submitted to the National Aeronautics and Space Administration our Project Proposal for the next step research directed toward further improvement of the FL approach

The effectiveness of atorvastatin in the prevention of stroke

Summary. The article examined the relationship between the risk of stroke and various profiles of lipid metabolism. The findings show that only statins, unlike many other lipid-lowering drugs, significantly reduce the risk of both primary and recurrent stroke. The discussion is focused on research findings demonstrating a lower risk of cerebral events during treatment with atorvastatin. It is stressed that in case of administration of generic drugs, the same level of efficiency and safety can only be guaranteed if the generic has a proven therapeutic equivalence to the original drug